NCT04818892View on ClinicalTrials.gov

Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease

CompletedOBSERVATIONAL

Enrollment

222

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions

IBDCovid19 Vaccine

Interventions

DIAGNOSTIC_TEST

Serological Assay for SARS-CoV-2

LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.

Trial Locations (1)

53705

University of Wisconsin, Madison

All Listed Sponsors

lead

University of Wisconsin, Madison

OTHER

NCT04818892 - Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter